Physician profile
Lynette Womble
NPI 1669653663
$2,098.00
in general payments reported to CMS, 2019-2025
21 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $227 · 2023: $502 · 2024: $688 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.43 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.42 | 2021-2025 | |
| Lilly USA, LLC | $245.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $213.54 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $173.50 | 2022-2025 | Trintellix |
| Novo Nordisk INC | $163.35 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $85.73 | 2022 | |
| Revance Therapeutics, INC. | $74.08 | 2025 | Daxxify |
| Phathom Pharmaceuticals, INC. | $51.68 | 2024-2025 | Voquezna |
| Pfizer INC. | $47.63 | 2021-2023 | |
| Galderma Laboratories, L.P. | $46.94 | 2024 | Dysport |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.00 | 2022-2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $42.91 | 2021-2024 | Farxiga, Breztri |
| Lundbeck LLC | $33.29 | 2023-2024 | Rexulti |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $22.80 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.17 | 2023 | Quviviq |
| Merz North America, INC. | $19.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.42 | 2023 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.78 | 2024 | Caplyta |
| Paratek Pharmaceuticals, INC. | $15.92 | 2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynette Womble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.